Hospital
DLP Wilson Medical Center LLC
DLP Wilson Medical Center LLC was paid $11.47M by Medicaid between Jan 2018 and Dec 2024, across 99 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoDLP WILSON MEDICAL CENTER LLC
WILSON, NC 27893
WILSON, NC 27893
33aNPI1215359922assigned 01/15/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.47M
24GClaims314,188
24DCodes billed99
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#47 of 92
Median peer was paid$11.47M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,945 | $1.42M | |
| 2019 | 60,647 | $1.62M | |
| 2020 | 42,527 | $788K | |
| 2021 | 42,259 | $1.28M | |
| 2022 | 36,434 | $1.84M | |
| 2023 | 45,789 | $2.37M | |
| 2024incomplete | 36,587 | $2.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 33,965 | 31,308 | $3.53M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 17,597 | 16,184 | $2.87M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.5% | 17,606 | 16,324 | $1.09M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 1,955 | 1,648 | $609K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.4% | 3,747 | 3,361 | $501K |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.0% | 245 | 158 | $348K |
| 80053 | Comprehensive metabolic panel | 2.2% | 27,361 | 24,336 | $253K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.9% | 5,310 | 2,868 | $213K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 34,362 | 30,419 | $209K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 11,538 | 10,024 | $193K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 4,664 | 4,326 | $188K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 5,862 | 5,384 | $171K |
87 more codes
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 498 | $128K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.0% | 275 | $117K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,898 | $82K |
| 80305 | <1% | 2,494 | $82K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,486 | $78K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 155 | $70K |
| 81001 | <1% | 21,830 | $70K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,449 | $67K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 406 | $66K |
| 36415 | Collection of venous blood by venipuncture | <1% | 35,949 | $60K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,860 | $54K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,799 | $45K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,263 | $29K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,387 | $28K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 885 | $28K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 43 | $24K |
| 84484 | <1% | 3,763 | $22K | |
| A9270 | Non-covered item or service | <1% | 34,895 | $22K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,088 | $20K |
| 81025 | <1% | 2,733 | $19K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 54 | $18K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 977 | $15K |
| J3490 | Unclassified drugs | <1% | 5,119 | $14K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 663 | $9K |
| 85730 | <1% | 2,295 | $9K | |
| 83690 | <1% | 1,422 | $8K | |
| 59025 | Fetal non-stress test | <1% | 207 | $8K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,416 | $6K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 215 | $6K |
| 80061 | Lipid panel | <1% | 494 | $6K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 371 | $6K |
| 85610 | <1% | 2,314 | $6K | |
| 82550 | <1% | 1,602 | $6K | |
| 83735 | <1% | 973 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 331 | $4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 84 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 119 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 444 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 344 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,358 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 752 | $3K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 176 | $2K |
| 94726 | <1% | 31 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 318 | $2K |
| 87081 | <1% | 280 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 804 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 47 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 199 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 155 | $1K |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 716 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 26 | $1K |
| 94729 | <1% | 46 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 97 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 307 | $1K |
| 87807 | <1% | 95 | $1K | |
| 11045 | <1% | 18 | $998.75 | |
| 94060 | <1% | 43 | $985.03 | |
| 82553 | <1% | 121 | $714.74 | |
| 87088 | <1% | 126 | $710.49 | |
| 73130 | <1% | 15 | $700.31 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 179 | $510.62 |
| 82948 | <1% | 201 | $507.61 | |
| 73630 | <1% | 15 | $434.85 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 14 | $414.37 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 27 | $390.61 |
| 84439 | <1% | 65 | $389.89 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 152 | $370.30 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 96 | $330.64 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 29 | $297.54 |
| 87070 | <1% | 96 | $241.42 | |
| 83605 | <1% | 32 | $224.86 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 124 | $153.83 |
| 82565 | <1% | 39 | $146.01 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 29 | $142.60 |
| J7999 | Compounded drug, not otherwise classified | <1% | 78 | $135.94 |
| 87205 | <1% | 96 | $113.92 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 41 | $113.38 |
| 87186 | <1% | 16 | $96.55 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 28 | $86.50 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 50 | $85.60 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 52 | $71.47 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 57 | $70.14 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 52 | $62.00 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 13 | $25.07 |
| 84520 | <1% | 39 | $14.34 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.